Suggested remit: To appraise the clinical and cost effectiveness of iptacopan within its marketing authorisation for treating complement 3 (C3) glomerulopathy.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6283
|
Provisional Schedule
| Committee meeting |
13 August 2025 |
| Expected publication |
08 January 2026 |
Project Team
Email enquiries
| External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors |
Novartis (iptacopan) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Kidney Care UK |
| |
Kidney Research UK |
| |
MPGN/DDD Support Group |
| |
National Kidney Federation |
| Professional groups |
Royal College of Pathologists |
| |
UK Kidney Association |
| Comparator companies |
Alexion Pharma (eculizumab) |
| |
Amgen (eculizumab) - not participating |
| |
Roche (mycophenolate mofetil) - not participating |
| |
Rosemont Pharmaceuticals (mycophenolate mofetil) - not participating |
| |
Samsung Bioepis (eculizumab) - not participating |
| |
Teva Pharma (mycophenolate mofetil) - not participating |
| |
Tillomed Laboratories (mycophenolate mofetil) - not participating |
| Evidence review group |
National Institute for Health Research Health Technology Assessment Programme (NETSCC) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
NHS Wales Joint Commissioning Committee |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
|
Date
|
Update
|
|
14 January 2025
|
Invitation to participate |
|
07 October 2024 - 04 November 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6283 |
|
07 October 2024
|
In progress. Scoping commencing |
|
28 April 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual